 |
市場調查報告書
商品編碼
1608839
眼部發炎治療市場：按藥物類別、按劑型、按分銷管道、按地區Eye Inflammation Treatment Market, By Drug Class, By Dosage Form, By Distribution Channel, By Geography |
||||||
眼部發炎治療市場預計到2024年將達到6.219億美元，預計到2031年將達到9.268億美元，2024年至2031年的複合年成長率為5.9%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2024年市場規模 | 6.219 億美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024年至2031年 |
| 預測 2024-2031 年複合年成長率： | 5.90% | 2031年價值預測 | 9.268 億美元 |
眼部發炎，又稱眼科疾病，是指眼睛腫脹或發炎。它通常是由感染疾病、過敏或其他疾病引起的。易患與老齡化相關的眼部疾病的老年人口不斷增加、全球結膜炎患者患病率不斷增加以及新產品的推出可能會推動對眼部發炎治療藥物和設備的需求。藥物傳遞和緩釋性的進步提高了治療效果和患者依從性。新治療方案的高成本和重磅藥物的專利到期是市場成長的挑戰。對新藥和藥物器材聯合治療的持續研究可能會提供市場成長機會。
市場動態
眼部發炎治療市場的成長是由於結膜炎和葡萄膜炎等眼部發炎盛行率的增加、影響眼睛健康的過敏和自體免疫疾病發病率的增加以及新藥的發布帶來的療效的提高所推動的。然而，生物製藥和細胞療法的高成本可能會阻礙市場成長。利用藥物和藥物輸送裝置的聯合治療的開拓、生物相似藥的出現以及新興市場的擴張可能為市場參與者提供成長機會。重磅藥物的專利到期和新眼科產品核准的嚴格法律規範可能會阻礙市場成長。
本研究的主要特點
該報告對全球眼部發炎治療市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（百萬美元）和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、業績和策略等參數，提供全球眼部發炎治療市場主要企業的概況。
本研究涵蓋的主要企業包括 GSK plc.、Merck &Co.Inc.、Alimera Sciences, Inc.、AbbVie Inc.、Teva Pharmaceutical Industries Ltd.、Akron Pharma Inc.、Intas Pharmaceuticals Ltd.、Mylan NV、Amgen Inc.、輝瑞公司、麥克勞茲製藥有限公司等。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球眼部發炎治療市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球眼部發炎治療市場的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 研究目的與前提
- 研究目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章 市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管場景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購場景
- 流行病學
- 管道分析
第4章 眼部發炎治療市場，依藥物類別，2019-2031
- 皮質類固醇
- 抗生素
- 單株抗體
- 抗真菌藥物
- 睫狀肌麻痺藥
- 其他
第5章 眼部發炎治療市場，按劑型，2019-2031
- 眼藥水
- 藥片
- 膠囊
- 其他
第6章眼部發炎治療市場，依通路，2019-2031
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 2019-2031 年眼部發炎治療市場（按地區）
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第8章 競爭格局
- GSK plc.
- Merck & Co. Inc.
- Alimera Sciences, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Akron Pharma Inc.
- Intas Pharmaceuticals Ltd.
- Mylan NV
- Amgen Inc.
- Pfizer Inc.
- Macleods Pharmaceuticals Ltd.
第9章 分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第10章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Eye inflammation treatment market is estimated to be valued at USD 621.9 Mn in 2024 and is expected to reach USD 926.8 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | 621.9 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.90% | 2031 Value Projection: | 926.8 Mn |
Eye inflammation, also known as ophthalmia, refers to the swelling and irritation of the eyes. It is usually caused by infections, allergies or other medical conditions. Rising geriatric population susceptible to age-related ocular disorders, growing prevalence of conjunctivitis cases worldwide and new product launches can boost demand for eye inflammation drugs and devices. Advancements in drug delivery methods and sustained release formulations have improved treatment effectiveness and patient compliance. High costs of newer treatment options and patent expiries of blockbuster drugs pose challenges for the market growth. Ongoing research on novel drugs and drug-device combination therapies can offer market growth opportunities.
Market Dynamics
Eye inflammation treatment market growth is driven by growing prevalence of eye inflammations like conjunctivitis and uveitis, increasing incidence of allergies and autoimmune diseases affecting eye health, and launch of newer drugs with improved efficacy. However, high costs of biologics and cell therapy can hamper the market growth. Development of combination therapies utilizing drugs and drug delivery devices, emergence of biosimilars, and expansion in emerging economies can offer growth opportunities for market players. Patent expiries of blockbuster drugs and stringent regulatory framework for approval of new ophthalmic products can hamper the market growth.
Key features of the study
This report provides in-depth analysis of the global eye inflammation treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eye inflammation treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK plc., Merck & Co. Inc., Alimera Sciences, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Akron Pharma Inc., Intas Pharmaceuticals Ltd., Mylan N.V., Amgen Inc., Pfizer Inc., and Macleods Pharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global eye inflammation treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global eye inflammation treatment market
Market Segmentation
- By Drug Class Insights (Revenue, USD Mn, 2019 - 2031)
- Corticosteroids
- Antibiotics
- Monoclonal Antibodies
- Antifungals
- Cycloplegic Agents
- Others
- By Dosage Form Insights (Revenue, USD Mn, 2019 - 2031)
- Eye Drops
- Tablets
- Capsules
- Others
- By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GSK plc.
- Merck & Co. Inc.
- Alimera Sciences, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Akron Pharma Inc.
- Intas Pharmaceuticals Ltd.
- Mylan N.V.
- Amgen Inc.
- Pfizer Inc.
- Macleods Pharmaceuticals Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Eye Inflammation Treatment Market, By Drug Class
- Eye Inflammation Treatment Market, By Dosage Form
- Eye Inflammation Treatment Market, By Distribution Channel
- Eye Inflammation Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Eye Inflammation Treatment Market, By Drug Class, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Antifungals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Cycloplegic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Eye Inflammation Treatment Market, By Dosage Form, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Eye Drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Eye Inflammation Treatment Market, By Distribution Channel, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Eye Inflammation Treatment Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alimera Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Akron Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Macleods Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
